Vaxcyte, Inc. financial data

Symbol
PCVX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
825 Industrial Road, Ste. 300, San Carlos, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
SutroVax, Inc. (to 4/3/2020)
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.38K % -10.6%
Debt-to-equity 7.22 % -11.4%
Return On Equity -28.8 % +22.8%
Return On Assets -26.9 % +22.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 109M shares +16.1%
Common Stock, Shares, Outstanding 109M shares +34.9%
Entity Public Float 4.1B USD +273%
Common Stock, Value, Issued 112K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 112M shares +29.6%
Weighted Average Number of Shares Outstanding, Diluted 112M shares +29.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 369M USD +88.3%
General and Administrative Expense 67.5M USD +48.7%
Operating Income (Loss) -511M USD -93.5%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -437M USD -78.3%
Earnings Per Share, Basic -4.29 USD/shares -24%
Earnings Per Share, Diluted -4.29 USD/shares -24%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 612M USD +60.7%
Other Assets, Current 2.09M USD
Assets, Current 1.52B USD +80.5%
Property, Plant and Equipment, Net 84.8M USD +458%
Operating Lease, Right-of-Use Asset 28.9M USD +47%
Other Assets, Noncurrent 46.1M USD +1071%
Assets 2.09B USD +107%
Accounts Payable, Current 21.7M USD +87%
Employee-related Liabilities, Current 3.09M USD +64.3%
Accrued Liabilities, Current 54.2M USD +195%
Liabilities, Current 87.1M USD +65.1%
Operating Lease, Liability, Noncurrent 20.2M USD +90.1%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 107M USD +69.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2.89M USD +6047%
Retained Earnings (Accumulated Deficit) -1.02B USD -75%
Stockholders' Equity Attributable to Parent 1.98B USD +110%
Liabilities and Equity 2.09B USD +107%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -159M USD -234%
Net Cash Provided by (Used in) Financing Activities 818M USD +1869%
Net Cash Provided by (Used in) Investing Activities -451M USD -0.66%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 109M shares +34.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 214M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 613M USD +60.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 288M USD +75.2%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 297M USD +74.2%
Operating Lease, Liability 27.4M USD +65.3%
Payments to Acquire Property, Plant, and Equipment 5.68M USD +1.23%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -434M USD -77.8%
Lessee, Operating Lease, Liability, to be Paid 34.7M USD +89.4%
Property, Plant and Equipment, Gross 95.1M USD +332%
Operating Lease, Liability, Current 7.2M USD +21.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.9M USD -57.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 9.84M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +13.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7.3M USD +319%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.99M USD -57.5%
Deferred Tax Assets, Operating Loss Carryforwards 135M USD +21.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.45M USD +154%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.08M USD
Operating Lease, Payments 8.11M USD +26.2%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 999K USD +40.3%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%